Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in New York: - Wilmot Cancer Center at Batavia — Batavia, New York
- Northwell Health Imbert Cancer Center — Bay Shore, New York
- Sands Cancer Center — Canandaigua, New York
- Memorial Sloan Kettering Commack — Commack, New York
- Noyes Memorial Hospital/Myers Cancer Center — Dansville, New York
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Sites in New York: - Montefiore Medical Center - Montefiore Medical Park — The Bronx, New York
- White Plains Hospital — White Plains, New York
Phase 3 Recruiting Industry
This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…
Sponsor: Pfizer
NCT ID: NCT07222566
Sites in New York: - New York Oncology Hematology — Albany, New York
- New York Oncology Hematology — Clifton Park, New York
- Hematology Oncology Associates of Rockland — Nyack, New York
Phase 3 Recruiting Industry
The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a…
Sponsor: Pfizer
NCT ID: NCT06758401
Sites in New York: - Hematology Oncology Associates of Rockland — Nyack, New York
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …
Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in New York: - Research Site — Buffalo, New York
- Research Site — East Syracuse, New York
- Research Site — Westbury, New York
Phase 3 Recruiting NIH
This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgic…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07388524
Sites in New York: - Hematology Oncology Associates of CNY at Camillus — Camillus, New York
- Hematology Oncology Associates of Central New York-East Syracuse — East Syracuse, New York
- Stony Brook University Medical Center — Stony Brook, New York
Phase 3 Recruiting Network
This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approa…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06686771
Sites in New York: - Northwell Health/Center for Advanced Medicine — Lake Success, New York
- Mount Sinai Chelsea — New York, New York
- Mount Sinai West — New York, New York
- Mount Sinai Hospital — New York, New York
- Manhattan Eye Ear and Throat Hospital — New York, New York
Phase 3 Recruiting Industry
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…
Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in New York: - Research Site — Stony Brook, New York
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-muta…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06793215
Sites in New York: - SUNY Upstate Medical University — Syracuse, New York
- Montefiore Einstein Cancer Center — The Bronx, New York
- Clinical Research Alliance — Westbury, New York
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in New York: - Nuvance Health — Poughkeepsie, New York
- Suny-Stony Brook University Cancer Center — Stony Brook, New York
- White Plains Hospital — White Plains, New York
Phase 3 Recruiting Industry
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in New York: - Roswell Park Cancer Institute ( Site 0184) — Buffalo, New York
- Hematology-Oncology Associates of CNY ( Site 0164) — East Syracuse, New York
- The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0216) — New York, New York
- Icahn School of Medicine at Mount Sinai ( Site 0116) — New York, New York
- Memorial Sloan Kettering Cancer Center ( Site 0137) — New York, New York
Phase 3 Recruiting Industry
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Sites in New York: - Local Institution - 0678 — Cooperstown, New York
- Ellis Hospital — Schenectady, New York
- White Plains Hospital — White Plains, New York
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07361510
Sites in New York: - Local Institution - 0224 — Laurelton, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Optum Medical Care, PC — Westbury, New York
Phase 3 Recruiting Academic/Other
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT02468024
Sites in New York: - New York University Langone Medical Center — New York, New York
- SUNY - Upsate Medical Centre — Syracuse, New York
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
Sponsor: AstraZeneca
NCT ID: NCT06868277
Sites in New York: - Research Site — Buffalo, New York
- Research Site — East Syracuse, New York
- Research Site — Fresh Meadows, New York
- Research Site — Rochester, New York
- Research Site — Westbury, New York
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
Sponsor: Zai Lab (Shanghai) Co., Ltd.
NCT ID: NCT07218146
Sites in New York: - Stony Brook Cancer Center — Stony Brook, New York
- Montefiore Medical Center — The Bronx, New York
Phase 3 Recruiting Industry
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advance…
Sponsor: NovoCure GmbH
NCT ID: NCT06216301
Sites in New York: - New York Cancer & Blood Specialists (NYCBS) — New Hyde Park, New York
- New York Cancer & Blood Specialists (NYCBS) — New York, New York
- University of Rochester Medical Center — Rochester, New York
- New York Cancer & Blood Specialists (NYCBS) — Shirley, New York
- New York Cancer & Blood Specialists (NYCBS) — The Bronx, New York
Phase 3 Recruiting Industry
This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
Sponsor: Daiichi Sankyo
NCT ID: NCT06203210
Sites in New York: - Clinical Research Alliance, Inc — Lake Success, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health Long Island — New York, New York
- New York University Cancer Center - Laura and Isaac — New York, New York
- Montefiore Medical Center Prime — The Bronx, New York
Phase 2, Phase 3 Recruiting Industry
A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07100080
Sites in New York: - Perlmutter Cancer Center at NYU Langone Hospital - Long Island — Mineola, New York
- NYU Langone Health — New York, New York
- Weill Cornell Medical College — New York, New York
- Rochester General Hospital Infectious Disease — Rochester, New York
Phase 3 Recruiting Industry
Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose t…
Sponsor: Boehringer Ingelheim
NCT ID: NCT07195695
Sites in New York: - Laura & Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York
- Memorial Sloan-Kettering Cancer Center — New York, New York
Phase 3 Recruiting Industry
This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no pr…
Sponsor: Daiichi Sankyo
NCT ID: NCT06899126
Sites in New York: - Clinical Research Alliance — Westbury, New York
Phase 3 Recruiting Industry
Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma K…
Sponsor: Nuvalent Inc.
NCT ID: NCT06765109
Sites in New York: - NYU Langone's Perlmutter Cancer Center — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Optum Medical Care, PC — Westbury, New York
Phase 3 Recruiting Industry
Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The g…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07190248
Sites in New York: - New York Oncology Hematology, P.C. ( Site 0119) — Albany, New York
- Wilmot Cancer Institute ( Site 0141) — Rochester, New York
Phase 3 Recruiting Industry
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants. The aim of the study is to see how effective the study drug…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT07410117
Sites in New York: - Memorial Sloan Kettering Cancer Center — New York, New York
Phase 3 Recruiting Industry
This phase III trial compares the effect of the combination of aglatimagene besadenovec and pembrolizumab versus standard of care docetaxel chemotherapy for the treatment of stage IV non-squamous, non-small cell lung cancer. Aglatimagene b…
Sponsor: Candel Therapeutics, Inc.
NCT ID: NCT07660094
Sites in New York: - Laura & Isaac Perlmutter Cancer Center at NYU Langone Health — New York, New York